Trials (Tartu University Hospital) - Revision history

Francine: /* Trials: How to access */

2025-12-14T14:10:54Z

Trials: How to access

← Older revision		Revision as of 14:10, 14 December 2025
Line 5:		Line 5:
	Go back to [[Tartu University Hospital]] page		Go back to [[Tartu University Hospital]] page

	=== Trials: How to ~~access~~ ===		=== Trials: How to participate ===
	'''Contact information:''' [https://www.kliinikum.ee/en/research-and-teaching/clinical-research-centre/ Click here to access].		'''Contact information:''' [https://www.kliinikum.ee/en/research-and-teaching/clinical-research-centre/ Click here to access].

Francine at 13:54, 14 December 2025

2025-12-14T13:54:21Z

← Older revision		Revision as of 13:54, 14 December 2025
Line 4:		Line 4:
	<span style="display:none">estoniacountry</span>		<span style="display:none">estoniacountry</span>
	Go back to [[Tartu University Hospital]] page		Go back to [[Tartu University Hospital]] page

			=== Trials: How to access ===
			'''Contact information:''' [https://www.kliinikum.ee/en/research-and-teaching/clinical-research-centre/ Click here to access].


	'''NCTID''': NCT04241185		'''NCTID''': NCT04241185
Line 686:		Line 690:
	<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>		<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>
	<span style="display:none">hasCancerType::unknown</span>		<span style="display:none">hasCancerType::unknown</span>
			<span style="display:none">isTrial</span>

Lucas: Update categories.

2025-12-06T12:42:26Z

Update categories.

← Older revision		Revision as of 12:42, 6 December 2025
Line 665:		Line 665:
	<span style="display:none">hasTrialTitle::Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)</span>		<span style="display:none">hasTrialTitle::Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)</span>
	<span style="display:none">hasTrialTitle::Chemotherapy Plus Surgery in Treating Women With Breast Cancer</span>		<span style="display:none">hasTrialTitle::Chemotherapy Plus Surgery in Treating Women With Breast Cancer</span>
			<span style="display:none">hasCancerType::C00-D48: All neoplasms</span>
			<span style="display:none">hasCancerType::C00-C97: All cancer types</span>
			<span style="display:none">hasCancerType::C00-C14: Mouth/throat cancers</span>
			<span style="display:none">hasCancerType::C15-C26: Digestive system cancers</span>
			<span style="display:none">hasCancerType::C30-C39: Lung/chest cancers</span>
			<span style="display:none">hasCancerType::C40-C41: Bone cancers</span>
			<span style="display:none">hasCancerType::C43-C44: Skin cancers/melanoma</span>
			<span style="display:none">hasCancerType::C45-C49: Soft tissue cancer</span>
			<span style="display:none">hasCancerType::C50: Breast cancer</span>
			<span style="display:none">hasCancerType::C51-C58: Female genitalia cancers</span>
			<span style="display:none">hasCancerType::C60-C63: Male genitalia cancer</span>
			<span style="display:none">hasCancerType::C64-C68: Urinary system cancers</span>
			<span style="display:none">hasCancerType::C69-C72: Eye and brain cancer</span>
			<span style="display:none">hasCancerType::C73-C75: Thyroid and other gland cancers</span>
			<span style="display:none">hasCancerType::C76-C80: Cancers of unknown or unspecified areas</span>
			<span style="display:none">hasCancerType::C81-C96: Cancers of the blood and immune system</span>
			<span style="display:none">hasCancerType::C97-C97: Cancers in multiple locations from the start</span>
			<span style="display:none">hasCancerType::D00-D09: Early-stage cancers not yet spread</span>
			<span style="display:none">hasCancerType::D10-D36: Benign tumour</span>
			<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>
			<span style="display:none">hasCancerType::unknown</span>

Francine at 16:30, 2 December 2025

2025-12-02T16:30:36Z

← Older revision		Revision as of 16:30, 2 December 2025
Line 2:		Line 2:
	<span style="display:none">forproviders</span>		<span style="display:none">forproviders</span>
	<span style="display:none">forresearchers</span>		<span style="display:none">forresearchers</span>
	<span style="display:none">~~estonia~~</span>		<span style="display:none">estoniacountry</span>
	Go back to [[Tartu University Hospital]] page		Go back to [[Tartu University Hospital]] page

Lucas: Update categories.

2025-12-02T14:01:00Z

Update categories.

@@ Line 1: / Line 1: @@
-{{forpatients}}
+<span style="display:none">forpatients</span>
-{{forproviders}}
+<span style="display:none">forproviders</span>
-{{forresearchers}}
+<span style="display:none">forresearchers</span>
-{{estonia}}
+<span style="display:none">estonia</span>
 Go back to [[Tartu University Hospital]] page
@@ Line 605: / Line 605: @@
   '''Recruitment Status''': COMPLETED
   '''Condition''': Breast Cancer

Victor at 23:36, 5 November 2024

2024-11-05T23:36:55Z

← Older revision		Revision as of 23:36, 5 November 2024
Line 2:		Line 2:
	{{forproviders}}		{{forproviders}}
	{{forresearchers}}		{{forresearchers}}
			{{estonia}}
	Go back to [[Tartu University Hospital]] page		Go back to [[Tartu University Hospital]] page

Francine at 14:20, 4 January 2024

2024-01-04T14:20:30Z

← Older revision		Revision as of 14:20, 4 January 2024
Line 45:		Line 45:
	'''Condition''': HPV Infection		'''Condition''': HPV Infection
	'''NCTID''': NCT05609968		'''NCTID''': NCT05609968
	'''Title''': [[hasTrialTitle::Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) 50% (MK-3475-D46)]]		'''Title''': [[hasTrialTitle::Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)]]
	'''Study Summary''': The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%).		'''Study Summary''': The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%).
	'''Sponsor''': Merck Sharp & Dohme LLC		'''Sponsor''': Merck Sharp & Dohme LLC

Francine at 14:20, 4 January 2024

2024-01-04T14:20:03Z

← Older revision		Revision as of 14:20, 4 January 2024
Line 45:		Line 45:
	'''Condition''': HPV Infection		'''Condition''': HPV Infection
	'''NCTID''': NCT05609968		'''NCTID''': NCT05609968
	'''Title''': [[hasTrialTitle::Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ~~≥50~~% (MK-3475-D46)]]		'''Title''': [[hasTrialTitle::Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) 50% (MK-3475-D46)]]
	'''Study Summary''': The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%).		'''Study Summary''': The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%).
	'''Sponsor''': Merck Sharp & Dohme LLC		'''Sponsor''': Merck Sharp & Dohme LLC

Francine at 14:17, 4 January 2024

2024-01-04T14:17:12Z

Show changes

Francine: Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to Tartu University Hospital page '''NCTID''': NCT04241185 '''Title''': Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) '''Study Summary''': This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT a..."

2023-12-01T20:47:18Z

Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to Tartu University Hospital page '''NCTID''': NCT04241185 '''Title''': Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) '''Study Summary''': This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT a..."

Show changes